These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of in vitro and in vivo developmental toxicity and pharmacokinetics of phenytoin in the rat. Beekhuijzen ME; Verhoef A; Klaassen R; Rompelberg CJ; Piersma AH Pharmacol Toxicol; 2000 Aug; 87(2):96-102. PubMed ID: 10989948 [TBL] [Abstract][Full Text] [Related]
6. Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations. Danielsson BR; Danielson K; Tomson T Teratology; 1995 Nov; 52(5):252-9. PubMed ID: 8838248 [TBL] [Abstract][Full Text] [Related]
7. Influence of honey on the pharmacokinetics of phenytoin in healthy rabbits. Sukriti ; Garg SK Methods Find Exp Clin Pharmacol; 2003 Jun; 25(5):367-70. PubMed ID: 12851659 [TBL] [Abstract][Full Text] [Related]
8. Single oral loading dose of phenytoin: a pharmacokinetics study. Ratanakorn D; Kaojarern S; Phuapradit P; Mokkhavesa C J Neurol Sci; 1997 Mar; 147(1):89-92. PubMed ID: 9094065 [TBL] [Abstract][Full Text] [Related]
9. Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI; Brase DA Drug Metab Rev; 1995; 27(3):449-69. PubMed ID: 8521750 [No Abstract] [Full Text] [Related]
10. The pharmacokinetics of agents used to treat status epilepticus. Browne TR Neurology; 1990 May; 40(5 Suppl 2):28-32. PubMed ID: 2185438 [TBL] [Abstract][Full Text] [Related]
11. Subtherapeutic free phenytoin levels following fosphenytoin therapy in status epilepticus. Koul R; Deleu D Neurology; 2002 Jan; 58(1):147-8. PubMed ID: 11781425 [No Abstract] [Full Text] [Related]
12. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. Deleu D; Aarons L; Ahmed IA Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995 [TBL] [Abstract][Full Text] [Related]
13. Interaction between phenytoin and ciprofloxacin. Otero MJ; Morán D; Valverde MP Ann Pharmacother; 1999 Feb; 33(2):251-2. PubMed ID: 10084426 [No Abstract] [Full Text] [Related]
14. Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. Bodmer M; Link B; Grignaschi N; Kummer O; Ruegg S; Haschke M; Krähenbühl S Ther Drug Monit; 2008 Feb; 30(1):120-4. PubMed ID: 18223475 [TBL] [Abstract][Full Text] [Related]
15. Problems with phenytoin administration in neurology/neurosurgery ITU patients receiving enteral feeding. Kitchen D; Smith D Seizure; 2001 Jun; 10(4):265-8. PubMed ID: 11466022 [TBL] [Abstract][Full Text] [Related]
16. Use of IV fosphenytoin pharmacokinetics to determine the loading dose for a clinical trial of canine status epilepticus. Coles LD; Leppik IE; Patterson EE; Rivers Z; Mishra U; Cloyd JC Epilepsia; 2015 Jun; 56(6):888-94. PubMed ID: 25952988 [TBL] [Abstract][Full Text] [Related]
18. Time for phenytoin concentration to peak: consequences of first-order and zero-order absorption. McCauley DL; Tozer TN; Winter ME Ther Drug Monit; 1989 Sep; 11(5):540-2. PubMed ID: 2815228 [TBL] [Abstract][Full Text] [Related]
19. Phenytoin toxicity: an easily missed cause of cerebellar syndrome. Brostoff JM; Birns J; McCrea D J Clin Pharm Ther; 2008 Apr; 33(2):211-4. PubMed ID: 18315788 [TBL] [Abstract][Full Text] [Related]
20. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. Neerati P; Ganji D; Bedada SK Eur J Pharm Sci; 2011 Sep; 44(1-2):27-31. PubMed ID: 21640186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]